Management of Alcoholic Liver Disease

Clinics in Liver Disease

Volumn 13, Issue 2, 2009, Pages 267-275

  Lucey, Michael R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Abstinence; Alcohol; Alcoholism; Cirrhosis; Hepatitis

Indexed keywords

ACAMPROSATE; BACLOFEN; COLCHICINE; CORTICOSTEROID; DISULFIRAM; ETANERCEPT; INFLIXIMAB; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PREDNISOLONE; PREDNISONE; PROPYLTHIOURACIL; S ADENOSYLMETHIONINE; SILYBUM MARIANUM EXTRACT; SILYMARIN; TOPIRAMATE;

ALCOHOL ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLISM; CLINICAL TRIAL; DIARRHEA; DRUG FATALITY; HUMAN; HYPOTHYROIDISM; INFECTION; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; REVIEW;

ALCOHOLISM; CLINICAL TRIALS AS TOPIC; HEPATITIS, ALCOHOLIC; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER DISEASES, ALCOHOLIC; LIVER TRANSPLANTATION;

EID: 65149084781     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.02.003     Document Type: Review

References (45)

1. Teli M.R., Day C.P., Burt A.D., et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 346 8981 (1995) 987-990
2. Lischner M.W., Alexander J.F., and Galambos J.T. Natural history of alcoholic hepatitis. I. The acute disease. Am J Dig Dis 16 6 (1971) 481-494
3. Powell Jr. W.J., and Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 44 3 (1968) 406-420
4. Fuller R.K. Definition and diagnosis of relapse to drinking. Liver Transpl Surg 3 3 (1997) 258-262
5. Weinrieb R.M., Van Horn D.H., McLellan A.T., et al. Interpreting the significance of drinking by alcohol-dependent liver transplant patients: fostering candor is the key to recovery. Liver Transpl 6 6 (2000) 769-776
6. Pfitzmann R., Schwenzer J., Rayes N., et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 13 (2007) 197-205
7. Lucey M.R., Connor J.T., Boyer T.D., et al., DIVERT Study Group. Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function. Am J Gastroenterol 103 7 (2008) 1698-1706
8. Weinrieb R.M., Van Horn D.H., McLellan A.T., et al. Drinking behavior and motivation for treatment among alcohol-dependent liver transplant candidates. J Addict Dis 20 2 (2001) 105-119
9. Weinrieb R.M., Van Horn D.H., McLellan A.T., et al. Alcoholism treatment after liver transplantation: lessons learned from a clinical trial that failed. Psychosomatics 42 2 (2001) 110-116
10. Matching alcoholism treatments to client heterogeneity: project MATCH three-year drinking outcomes. Alcohol Clin Exp Res 22 6 (1998) 1300-1311
11. Garbutt J.C., West S.L., Carey T.S., et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 281 (1999) 1318-1325
12. Garbutt J.C., and Flannery B. Baclofen for alcoholism. Lancet 370 9603 (2007) 1884-1885
13. Vanjak D., Samuel D., Gosset F., et al. Fulminant hepatitis induced by disulfiram in a patient with alcoholic cirrhosis. Survival after liver transplantation. Gastroenterol Clin Biol 13 (1989) 1075-1078
14. Forns X., Caballería J., Bruguera M., et al. Disulfiram-induced hepatitis. Report of four cases and review of the literature. J Hepatol 21 (1994) 853-857
15. Anton R.F. Naltrexone for the management of alcohol dependence. N Engl J Med 359 (2008) 715-721
16. Krystal J.H., Cramer J.A., Krol W.F., et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med 345 (2001) 1734-1739
17. Anton R.F., O'Malley S.S., Ciraulo D.A., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295 (2006) 2003-2017
18. Garbutt J.C., Kranzler H.R., O'Malley S.S., et al., Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293 (2005) 1617-1625
19. Lucey M.R., Silverman B.L., Illeperuma A., et al. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res 32 (2008) 498-504
20. Whitworth A.B., Fischer F., Lesch O.M., et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347 9013 (1996) 1438-1442
21. Johnson B.A., Rosenthal N., Capece J.A., et al., Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298 14 (2007) 1641-1651
22. Johnson B.A., Rosenthal N., Capece J.A., et al., Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 168 11 (2008) 1188-1199
23. Addolorato G., Leggio L., Ferrulli A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370 9603 (2007) 1915-1922
24. Mathurin P., Mendenhall C.L., Carithers Jr. R.L., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 36 (2002) 480-487
25. Mathurin P., Abdelnour M., Ramond M.J., et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 38 (2003) 1363-1369
26. Louvet A., Naveau S., Abdelnour M., et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 45 (2007) 1348-1354
27. Rambaldi A., Iaquinto G., and Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev 1 (2003) CD003045
28. Naveau S., Chollet-Martin S., Dharancy S., et al., Foie-Alcool group of the Association Francaise pour l'Etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39 (2004) 1390-1397
29. Menon K.V., Stadheim L., Kamath P.S., et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 99 (2004) 255-260
30. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 1637-1648
31. Louvet A., Diaz E., Dharancy S., et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 48 (2008) 465-470
32. Stickel F., Hoehn B., Schuppan D., et al. Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 18 (2003) 357-373
33. Mezey E., Potter J.J., Rennie-Tankersley L., et al. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 1 (2004) 40-46
34. Stewart S., Prince M., Bassendine M., et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 47 (2007) 277-283
35. Veldt B.J., Lainé F., Guillygomarc'h A., et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 36 (2002) 93-98
36. Frieden T.R., Ozick L., McCord C., et al. Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis. Hepatology 29 (1999) 883-888
37. Corrao G., and Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 27 (1998) 914-919
38. Orrego H., Blake J.E., Blendis L.M., et al. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 317 (1987) 1421-1427
39. Kershenobich D., Vargas F., Garcia-Tsao G., et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 318 (1988) 1709-1713
40. Mato J.M., Cámara J., Fernández de Paz J., et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 30 (1999) 1081-1089
41. Orrego H., Blake J.E., Blendis L.M., et al. Long-term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop-out rates and of continued alcohol consumption in a clinical trial. J Hepatol 20 (1994) 343-349
42. Morgan T.R., Weiss D.G., Nemchausky B., et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 128 (2005) 882-890
43. Pares A., Planas R., Torres M., et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 4 (1998) 615-621
44. Lieber C.S., Weiss D.G., Groszmann R., et al., For the Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 27 (2003) 1765-1772
45. Lucey M.R. Liver transplantation for alcoholic liver disease. Clin Liver Dis 11 (2007) 283-289